Omeros Corporation (NASDAQ:OMER) – Equities researchers at Cantor Fitzgerald issued their FY2016 EPS estimates for Omeros Corporation in a research report issued to clients and investors on Tuesday. Cantor Fitzgerald analyst E. Piros anticipates that the brokerage will post earnings per share of ($1.63) for the year. Cantor Fitzgerald currently has a “Buy” rating and a $21.00 target price on the stock. Cantor Fitzgerald also issued estimates for Omeros Corporation’s FY2017 earnings at ($0.53) EPS.

Omeros Corporation (NASDAQ:OMER) last issued its earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.40) by $0.06. The firm earned $11.30 million during the quarter, compared to analyst estimates of $11.64 million. During the same quarter in the previous year, the business posted ($0.53) EPS. Omeros Corporation’s revenue was up 253.1% compared to the same quarter last year. COPYRIGHT VIOLATION NOTICE: “Omeros Corporation (OMER) Forecasted to Earn FY2016 Earnings of ($1.63) Per Share” was published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another publication, it was stolen and republished in violation of international copyright laws. The correct version of this news story can be read at http://www.watchlistnews.com/omeros-corporation-omer-forecasted-to-earn-fy2016-earnings-of-1-63-per-share/1061079.html.

Earnings History and Estimates for Omeros Corporation (NASDAQ:OMER)

Several other research analysts have also recently issued reports on OMER. FBR & Co reaffirmed an “outperform” rating and issued a $38.00 price target on shares of Omeros Corporation in a report on Tuesday, October 18th. Maxim Group set a $19.00 price target on Omeros Corporation and gave the company a “buy” rating in a report on Wednesday, November 2nd. Zacks Investment Research raised Omeros Corporation from a “sell” rating to a “hold” rating in a report on Wednesday, October 19th. WBB Securities reaffirmed a “buy” rating and issued a $75.00 price target on shares of Omeros Corporation in a report on Thursday, November 17th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $56.00 price target on shares of Omeros Corporation in a report on Friday, October 21st. One analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $33.23.

Omeros Corporation (NASDAQ:OMER) opened at 9.33 on Friday. Omeros Corporation has a one year low of $7.20 and a one year high of $16.80. The firm’s market cap is $400.40 million. The company has a 50-day moving average price of $10.96 and a 200-day moving average price of $10.78.

Several institutional investors have recently bought and sold shares of the company. Bank of Montreal Can increased its position in Omeros Corporation by 20.2% in the third quarter. Bank of Montreal Can now owns 2,015,248 shares of the biopharmaceutical company’s stock worth $22,490,000 after buying an additional 338,263 shares during the period. Wedbush Securities Inc. boosted its stake in shares of Omeros Corporation by 8.6% in the third quarter. Wedbush Securities Inc. now owns 92,635 shares of the biopharmaceutical company’s stock worth $1,034,000 after buying an additional 7,372 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its stake in shares of Omeros Corporation by 1.2% in the second quarter. State Board of Administration of Florida Retirement System now owns 30,737 shares of the biopharmaceutical company’s stock worth $323,000 after buying an additional 351 shares in the last quarter. Bourgeon Capital Management LLC acquired a new stake in shares of Omeros Corporation during the second quarter worth about $158,000. Finally, Capital Fund Management S.A. acquired a new stake in shares of Omeros Corporation during the third quarter worth about $245,000. 52.05% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Omeros Corporation (OMER) Forecasted to Earn FY2016 Earnings of ($1.63) Per Share” was published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another publication, it was stolen and republished in violation of international copyright laws. The correct version of this news story can be read at http://www.watchlistnews.com/omeros-corporation-omer-forecasted-to-earn-fy2016-earnings-of-1-63-per-share/1061079.html.

In other news, CEO Gregory A. Md Demopulos sold 306,124 shares of the company’s stock in a transaction on Wednesday, December 7th. The shares were sold at an average price of $10.66, for a total value of $3,263,281.84. Following the transaction, the chief executive officer now directly owns 1,987,025 shares of the company’s stock, valued at $21,181,686.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Gregory A. Md Demopulos sold 306,120 shares of the company’s stock in a transaction on Friday, December 2nd. The stock was sold at an average price of $11.58, for a total transaction of $3,544,869.60. Following the completion of the transaction, the chief executive officer now directly owns 1,801,381 shares in the company, valued at $20,859,991.98. The disclosure for this sale can be found here. 13.60% of the stock is currently owned by insiders.

Omeros Corporation Company Profile

Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.

5 Day Chart for NASDAQ:OMER

Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.